Patritumab Deruxtecan (HER3-DXd) PopPK
Indication: EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
Population PK simulator for patritumab deruxtecan (HER3-DXd) — HER3-directed ADC with DXd payload for EGFR-mutant NSCLC. Two-compartment ADC model with body-weight covariate (exponent 0.72) linked to one-compartment DXd payload. Standard dose 5.6 mg/kg Q3W. Based on Guo et al. 2024 CPT:PSP. Compare DXd payload exposure vs T-DXd and Dato-DXd.
Drug Overview
Clinical Context
- Molecular Target
- HER3 (ERBB3)
- Drug Class
- Antibody-Drug Conjugate (ADC)
- Therapeutic Area
- Oncology / NSCLC
- Indication
- EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
- Route of Administration
- IV Infusion
Model Information
- Model Type
- Population PK (2-CMT ADC + 1-CMT DXd Payload)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
Additional Parameters
| Parameter | Value |
|---|---|
| k12 | 0.18 |
| k21 | 0.28 |
| ADC CL | 0.38 |
| DXd Vd | 580 |
| Standard Dose | 5.6 |
| DXd Payload CL | 45 |
| ADC V1 (Central) | 3.2 |
| BW Exponent on CL | 0.72 |
| ADC V2 (Peripheral) | 1.8 |
| Payload Release Rate (kr) | 0.012 |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Patritumab Deruxtecan (HER3-DXd) allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK (2-CMT ADC + 1-CMT DXd Payload) model characterizes the pharmacokinetics of this antibody-drug conjugate (adc) following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Patritumab Deruxtecan (HER3-DXd) PK simulator?
This is a free, interactive pharmacokinetic simulator for Patritumab Deruxtecan (HER3-DXd) used in EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Patritumab Deruxtecan (HER3-DXd) belong to?
Patritumab Deruxtecan (HER3-DXd) is classified as a Antibody-Drug Conjugate (ADC) that targets HER3 (ERBB3). It is used in the Oncology / NSCLC therapeutic area.
What route of administration does this model simulate?
This simulator models IV Infusion administration of Patritumab Deruxtecan (HER3-DXd). The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK (2-CMT ADC + 1-CMT DXd Payload) model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Mirvetuximab Soravtansine (ELAHERE) PopPK
FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
poppk model of osimertinib
Ready to Simulate?
Launch the Patritumab Deruxtecan (HER3-DXd) simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community